JP2022516439A5 - - Google Patents

Info

Publication number
JP2022516439A5
JP2022516439A5 JP2021535930A JP2021535930A JP2022516439A5 JP 2022516439 A5 JP2022516439 A5 JP 2022516439A5 JP 2021535930 A JP2021535930 A JP 2021535930A JP 2021535930 A JP2021535930 A JP 2021535930A JP 2022516439 A5 JP2022516439 A5 JP 2022516439A5
Authority
JP
Japan
Prior art keywords
seq
represented
chain variable
nos
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516439A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/126903 external-priority patent/WO2020125744A1/zh
Publication of JP2022516439A publication Critical patent/JP2022516439A/ja
Publication of JP2022516439A5 publication Critical patent/JP2022516439A5/ja
Pending legal-status Critical Current

Links

JP2021535930A 2018-12-21 2019-12-20 二特異性タンパク質 Pending JP2022516439A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201811573634.0 2018-12-21
CN201811573634 2018-12-21
CN201811606887.3 2018-12-27
CN201811606887 2018-12-27
PCT/CN2019/126903 WO2020125744A1 (zh) 2018-12-21 2019-12-20 双特异性蛋白

Publications (2)

Publication Number Publication Date
JP2022516439A JP2022516439A (ja) 2022-02-28
JP2022516439A5 true JP2022516439A5 (https=) 2023-01-05

Family

ID=71102514

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535930A Pending JP2022516439A (ja) 2018-12-21 2019-12-20 二特異性タンパク質

Country Status (11)

Country Link
US (1) US20220153853A1 (https=)
EP (1) EP3901173A4 (https=)
JP (1) JP2022516439A (https=)
KR (1) KR20210109552A (https=)
CN (2) CN115947849A (https=)
AU (1) AU2019410643A1 (https=)
BR (1) BR112021011595A2 (https=)
CA (1) CA3123979A1 (https=)
MX (1) MX2021007444A (https=)
TW (1) TW202024134A (https=)
WO (1) WO2020125744A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022083720A1 (zh) * 2020-10-23 2022-04-28 江苏恒瑞医药股份有限公司 Glp1-gcgr抗体融合蛋白变体及包含其的组合物
CN114685644A (zh) * 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 一种人glp-1多肽变体及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1997046584A1 (de) 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
EP1061946B1 (en) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するglp−1のglp−1誘導体及びエキセンジン
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
EP1696962A2 (en) 2003-12-18 2006-09-06 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
ATE553124T1 (de) 2005-06-13 2012-04-15 Imp Innovations Ltd Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
CN1935846A (zh) 2005-09-14 2007-03-28 王庆华 一种用于治疗糖尿病的融合蛋白及其制备方法和应用
CN100556455C (zh) 2005-09-14 2009-11-04 王庆华 一种用于预防和治疗i型糖尿病的药物复合物及其应用
DE602005017628D1 (de) 2005-09-22 2009-12-24 Biocompatibles Uk Ltd Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
MX2008013459A (es) * 2006-04-20 2008-10-30 Amgen Inc Composiciones de anticuerpos glucagon/compuesto de peptido 1 similar al glucagon (glp-1).
JP2009534423A (ja) 2006-04-20 2009-09-24 アムジェン インコーポレイテッド Glp−1化合物
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
AR070844A1 (es) 2008-03-27 2010-05-05 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
EP2370462B1 (en) 2008-12-15 2014-07-16 Zealand Pharma A/S Glucagon analogues
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
KR20120056800A (ko) 2009-09-08 2012-06-04 (주)네오팜 글루글루카곤 수용체에 대한 항체와 이의 사용
EP2496249B1 (en) * 2009-11-03 2016-03-09 Amylin Pharmaceuticals, LLC Glp-1 receptor agonist for use in treating obstructive sleep apnea
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2552951A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
US8771696B2 (en) * 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US20130344524A1 (en) * 2011-03-08 2013-12-26 Sanwa Kagaku Kenkyusho Co., Ltd. Analysis method
CN102949730A (zh) 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 特异结合glp-1受体的药物融合体
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
WO2014181229A2 (en) 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
CN104231083A (zh) * 2013-06-09 2014-12-24 杭州鸿运华宁生物医药工程有限公司 抗胰高血糖素受体的抗体及其用途
JP2016534984A (ja) 2013-10-01 2016-11-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited アフィニティークロマトグラフィーのためおよび治療薬の半減期の延長のための化合物
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
WO2015189698A2 (en) * 2014-06-08 2015-12-17 Beijing Cosci-Remd Bio Med Tech Company Ltd Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
CN104293834B (zh) 2014-10-11 2018-03-23 上海兴迪金生物技术有限公司 GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法
CN104327187B (zh) 2014-10-11 2018-06-08 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
JP6861641B2 (ja) 2015-04-02 2021-04-21 アールイーエムディー バイオセラピューティクス,インコーポレイテッドREMD Biotherapeutics,Inc グルカゴン受容体アンタゴニスト抗体を用いた肥満症および非アルコール性脂肪性肝疾患または非アルコール性脂肪性肝炎を治療するための方法
EP3394091A4 (en) 2015-12-09 2019-12-18 Merck Sharp & Dohme Corp. CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
EP3573651A4 (en) * 2017-01-27 2020-10-14 NGM Biopharmaceuticals, Inc. GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE
CN110357959B (zh) * 2018-04-10 2023-02-28 鸿运华宁(杭州)生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用

Similar Documents

Publication Publication Date Title
US20220332819A1 (en) Binding agents
US20250368737A1 (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
AU2019246401B2 (en) CD47 binding agents
JP2022126783A (ja) Fcrn抗体及びその使用方法
US11155618B2 (en) Anti-TREM-1 antibodies and uses thereof
EP3714901A1 (en) Lag-3 antibody pharmaceutical composition and use thereof
EP3659586B1 (en) Sost antibody pharmaceutical composition and uses thereof
CN114980926A (zh) 一种抗il-4r抗体药物组合物及其用途
CN120603852A (zh) 一种fap/cd40结合分子的药物组合物及其医药用途
JP2022516439A5 (https=)
KR20210053294A (ko) 항-tim3 항체 제약 조성물 및 이의 용도
TWI747098B (zh) 抗angptl3/8複合物抗體及其使用方法
EP4375298A1 (en) Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application
US20260042865A1 (en) Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases
JP2022527790A5 (https=)
US20260083841A1 (en) Bispecific Molecule Stabilizing Composition
US12617853B2 (en) Low pH pharmaceutical composition comprising T cell engaging antibody constructs
WO2025076131A1 (en) Compostions of multispecific antigen binding polypeptides and methods of use
AU2024354938A1 (en) Compostions of multispecific antigen binding polypeptides and methods of use
WO2025186043A1 (en) Pharmaceutical formulation for anti-ccr8 antibodies
HK40111253A (zh) 抗pacap抗体的组合物和方法
HK40130468A (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
HK40130469A (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
HK40078655A (en) Pharmaceutical composition containing anti-il-4r antibody and use thereof
HK40018569A (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs